Selected Publication

1. Ahmed SAA, Quattrocchi A, KaranisCryptosporidium sp. infection in solid organ transplant recipients: A systematic review and meta-analysis. Pathog Glob Health. 2024 Jun;118(4):305-316. doi: 10.1080/20477724.2023.2290379.
2. Ahmed SAA, Mohamed SF, El-Mahallawy HS, Quattrocchi A, Karanis P. Gastrointestinal parasitic infections: Prevalence and risk factors in West Ismailia, Arab Republic of Egypt. Gut Pathog. 2024 Jun 19;16(1):29. doi: 10.1186/s13099-024-00622-y.
3. Ahmed SAA, Quattrocchi A, Elzagawy SM, Karanis P, Gad SEM. Diagnostic Performance of Toluidine Blue Stain for Direct Wet Mount Detection of CryptosporidiumOocysts: Qualitative and Quantitative Comparison to the Modified Ziehl-Neelsen Stain. Diagnostics (Basel). 2023 Aug 1;13(15):2557. doi: 10.3390/diagnostics13152557.
4. Quattrocchi A, Mamais I, Tsioutis C, Christaki E, Constantinou C, Koliou M, Pana ZD, Silvestros V, Theophanous F, Haralambous C, Stylianou A, Sotiriou S, Athanasiadou M, Kyprianou T, Demetriou A, Demetriou CA, Kolokotroni O, Gregoriou I, Paphitou N, Panos G, Kostrikis L, Karayiannis P, Petrikkos G, Agathangelou P, Mixides G, Siakallis G, Hadjihannas L, Palazis L, Vavlitou A, Matsentidou-Timiliotou C, Koukios D, Adamidi T, Frangopoulos F, Constantinou E, Nikolopoulos G. Extensive Testing and Public Health Interventions for the Control of COVID-19 in the Republic of Cyprus between March and May 2020. J Clin Med. 2020 Nov 8;9(11):3598. doi: 10.3390/jcm9113598.
5. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Colomb-Cotinat M, Kretzschmar ME, Devleesschauwer B, Cecchini M, Ouakrim DA, Oliveira TC, Struelens MJ, Suetens C, Monnet DL; Burden of AMR Collaborative Group. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4.
6. Pallari CT, Achilleos S, Quattrocchi A, Gabel J, Critselis E, Athanasiadou M, Rahmanian Haghighi MR, Papatheodorou S, Liu T, Artemiou A, Rodriguez-Llanes JM, Bennett CM, Zimmermann C, Schernhammer E, Bustos Sierra N, Ekelson R, Lobato J, Macedo L, Mortensen LH, Critchley J, Goldsmith L, Denissov G, Le Meur N, Kandelaki L, Athanasakis K, Binyaminy B, Maor T, Stracci F, Ambrosio G, Davletov K, Glushkova N, Martial C, Chan Sun M, Hagen TP, Chong M, Barron M, Łyszczarz B, Erzen I, Arcos Gonzalez P, Burström B, Pidmurniak N, Verstiuk O, Huang Q, Polemitis A, Charalambous A, Demetriou CA. Magnitude and determinants of excess total, age-specific and sex-specific all-cause mortality in 24 countries worldwide during 2020 and 2021: results on the impact of the COVID-19 pandemic from the C-MOR project. BMJ Glob Health. 2024 Apr 18;9(4):e013018. doi: 10.1136/bmjgh-2023-013018. PMID: 38637119; PMCID: PMC11029481.
7. Beeks VV, Achilleos S, Quattrocchi A., et al. Cause-Specific Excess Mortality During the COVID-19 Pandemic (2020–2021) in 12 Countries of the C-MOR Consortium. J Epidemiol Glob Health 14, 337–348 (2024). https://doi.org/10.1007/s44197-024-00242-4
8. Kouis P, Galanakis E, Michaelidou E, Kinni P, Michanikou A, Pitsios C, Perez J, Achilleos S, et al. Improved childhood asthma control after exposure reduction interventions for desert dust and anthropogenic air pollution: the MEDEA randomised controlled trial. Thorax 2024;79:495-507. https://doi.org/10.1136/thorax-2023-220877
9. Eyre A, Stein GY, Chen J, Alon D. Physician performance scores used to predict emergency department admission numbers and excessive admissions burden. BMJ Health Care Inform. 2024 Sep 17;31(1):e101080. doi: 10.1136/bmjhci-2024-101080. PMID: 39289004.
10. Weiss O, Eyre A, Ellenbogen DA, Stein GY. The impact of hospitalization on inappropriate prescribing and polypharmacy in older patients: A descriptive cross-sectional study. Pharmacoepidemiol Drug Saf. 2024 May;33(5):e5812. doi: 10.1002/pds.5812. PMID: 38720413.
11. Spanakis M, Alon-Ellenbogen D, Ioannou P, Spernovasilis N. Antibiotics and Lipid-Modifying Agents: Potential Drug-Drug Interactions and Their Clinical Implications. Pharmacy (Basel). 2023 Aug 19;11(4):130. doi: 10.3390/pharmacy11040130. PMID: 37624085; PMCID: PMC10457919.
12. Mudrik-Zohar H, Alon D, Nacasch N, Sternschuss A, Greenberg M, Benchetrit S, Gavrieli R, Zitman-Gal T, Cohen-Hagai K. Neutrophil reactive oxygen formation, bacterial infections and mortality in malnourished hemodialysis patients: Evaluation of clinical outcomes. Semin Dial. 2023 Sep-Oct;36(5):399-406. doi: 10.1111/sdi.13168. Epub 2023 Jul 9. PMID: 37424019.
13. Alon D, Paitan Y, Robinson E, Ganor N, Lipovetsky J, Yerushalmi R, Cohen CJ, Raiter A. Downregulation of CD45 Signaling in COVID-19 Patients Is Reversed by C24D, a Novel CD45 Targeting Peptide. Front Med (Lausanne). 2021 Aug 3;8:675963. doi: 10.3389/fmed.2021.675963. PMID: 34414199; PMCID: PMC8369232.
14. Ozbil E, Ilktac M, Ogmen S, Isbilen O, Duran Ramirez JM, Gomez J, Walker JN, Volkan E. In vitro antibacterial, antibiofilm activities, and phytochemical properties of Posidonia oceanica (L.) Delile: An endemic Mediterranean seagrass. Heliyon. 2024 Aug 3;10(15):e35592. doi: 10.1016/j.heliyon.2024.e35592. PMID: 39170414; PMCID: PMC11336879.
15. Ergoren MC*, Akan G*, Volkan E*, Kandemis E, Evren EU, Evren H, Volkan E, Tuncel G, Suer K, Sanlidag T. The “vaccine” hubbub: Viral load comparisons of SARS-CoV-2 Delta and Omicron variants against different vaccine-booster vaccine combinations. J Med Virol. 2023 Jan;95(1):e28309. doi: 10.1002/jmv.28309. Epub 2022 Nov 19. PMID: 36377303.
16. Barin B, Kasap U, Selçuk F, Volkan E, Uluçkan Ö. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe. 2022 Apr;3(4):e274-e283. doi: 10.1016/S2666-5247(21)00305-0. Epub 2022 Feb 9. PMID: 35165669; PMCID: PMC8828370.
17. Volkan E. COVID-19: Structural Considerations for Virus Pathogenesis, Therapeutic Strategies and Vaccine Design in the Novel SARS-CoV-2 Variants Era. Mol Biotechnol. 2021 Oct;63(10):885-897. doi: 10.1007/s12033-021-00353-4. Epub 2021 Jun 18. PMID: 34145550; PMCID: PMC8213040.
18. Jafaar HJ, Isbilen O, Volkan E, Sariyar G. Alkaloid profiling and antimicrobial activities of Papaver glaucum and decaisnei. BMC Res Notes. 2021 Sep 8;14(1):348. doi: 10.1186/s13104-021-05762-x. PMID: 34496958; PMCID: PMC8424945.
19. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, et al. Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
20. Lehrnbecher T, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021;22(6):e270-e280. doi: 10.1016/S1470-2045(20)30725-7.
21. Groll AH, Pana D, et al. 8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation. Lancet Oncol. 2021 Jun;22(6):e254-e269. doi: 10.1016/S1470-2045(20)30723-3. Epub 2021 Mar 31.
22. Pana ZD, et al. Fighting the hidden pandemic of antimicrobial resistance in paediatrics: recommendations from the International Pediatric Association.  Paediatr Open. 2023 Jul;7(1):e002084. doi: 10.1136/bmjpo-2023-002084.
23. Bethe U, Pana ZD, et al. Innovative approaches for vaccine trials as a key component of pandemic preparedness – a white paper. 2024 Jul 17. doi: 10.1007/s15010-024-02347-1.
24. Fisher BT, Zaoutis TE, Xiao R, Wattier RL, Castagnola E, Pana ZD, et al. Comparative Effectiveness of Echinocandins vs Triazoles or Amphotericin B Formulations as Initial Directed Therapy for Invasive Candidiasis in Children and Adolescents. Pediatric Infect Dis Soc. 2021 piab024. doi: 10.1093/jpids/piab024.
25. Warris A, Pana ZD, et al. EUROCANDY Study Group. Etiology and Outcome of Candidemia in Neonates and Children in Europe: An 11-year Multinational Retrospective Study.  Pediatr Infect Dis J. 2020;39(2):114-120.
26. Tamma PD, Sharara SL, Pana ZD, et al. Molecular Epidemiology of Ceftriaxone Non-Susceptible Enterobacterales Isolates in an Academic Medical Center in the United States. Open Forum Infect Dis. 2019;6(8):ofz353.
27. First report of Acanthamoeba isolation in a recreational hot spring in the Philippines. Parado W 3rd, Quito YC, Mondelo KN, Nicdao EJA, Ortiz R, Perez JC, Reyes AF, Arada MC, Padua MFFE, Milanez GJ, Karanis P. J Water Health. 2024 Sep;22(9):1677-1682. doi: 10.2166/wh.2024.156. Epub 2024 Aug 8.PMID: 39340380
28. Blastocystis species growth inhibition in vitro by plant extracts. Ahmed SAA, Schou C, Mokhtar AB, Karanis P, Gad SEM.Microb Pathog. 2024 Nov;196:106970. doi: 10.1016/j.micpath.2024.106970. Epub 2024 Sep 21.PMID: 39307197
29. Waterborne Cryptosporidium species and Giardia duodenalis in resources of MENA: A systematic review and meta-analysis. Ayed LB, Ahmed SAA, Boughattas S, Karanis P.J Water Health. 2024 Aug;22(8):1491-1515. doi: 10.2166/wh.2024.107. Epub 2024 Jun 26.PMID: 39212283
30. Editorial: Impact and control of food- and waterborne protozoan parasites.
31. Matos O, Karanis P, Razakandrainibe R.Front Microbiol. 2024 Aug 6;15:1466883. doi: 10.3389/fmicb.2024.1466883. eCollection 2024.PMID: 39165574 Free PMC article. No abstract available.
32. Unveiling risks in healthy food: Vegetables and fruits are linked to the distribution chain of protozoan parasites. Vafae Eslahi A, Mamedova S, Nassiba R, Karanis P.Food Microbiol. 2024 Oct;123:104592. doi: 10.1016/j.fm.2024.104592. Epub 2024 Jul 3.PMID: 39038884 Review.
33. The Prevalence of Cryptosporidium and Giardia duodenalis in Marmota himalayana (Rodentia: Sciuridae) in the Qinghai Tibetan Plateau area, China.
34. Ma L, Jian Y, Wang G, Cai Q, Wang G, Li X, Zhang X, Karanis P.Iran J Parasitol. 2024 Apr-Jun;19(2):162-170. doi: 10.18502/ijpa.v19i2.15852.PMID: 39011525 Free PMC article.
35. Prevalence of intestinal protozoan parasites among Asian schoolchildren: a systematic review and meta-analysis. Abdoli A, Olfatifar M, Eslahi AV, Moghadamizad Z, Nowak O, Pirestani M, Karimipour-Saryazdi A, Badri M, Karanis P. 2024 Jul 9. doi: 10.1007/s15010-024-02339-1. Online ahead of print.PMID: 38982017 Review.
36. Gastrointestinal parasitic infections: Prevalence and risk factors in West Ismailia, Arab Republic of Egypt. Ahmed SAA, Mohamed SF, El-Mahallawy HS, Quattrocchi A, Karanis P.Gut Pathog. 2024 Jun 19;16(1):29. doi: 10.1186/s13099-024-00622-y.PMID: 38898500 Free PMC article.
37. A global systematic review and meta-analysis on the babesiosis in dogs with special reference to Babesia canis.Abdoli A, Olfatifar M, Badri M, Zaki L, Bijani B, Pirestani M, Hatam-Nahavandi K, Eslahi AV, Karanis P.Vet Med Sci. 2024 May;10(3):e1427. doi: 10.1002/vms3.1427.PMID: 38695207 Free PMC article.
38. Cryptosporidium and Eimeria spp. (Apicomplexa: Eimeriorina) of freshwater Cyprinid fish species in the Kura River basin in Azerbaijan territory.
39. Mamedova S, Karanis P.J Water Health. 2024 Apr;22(4):773-784. doi: 10.2166/wh.2024.025. Epub 2024 Mar 26.PMID: 38678429
40. Miliotou N. Androulla and Papadopoulou C. Lefkothea. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Current Pharmaceutical Biotechnology, Volume 19, Issue 1, 2018, Apr. DOI: 10.2174/1389201019666180418095526
41. Vizirianakis S. Ioannis, Miliotou N. Androulla, Mystridis A. George, Andriotis G. Eleftherios, Andreadis Ioannis, Papadopoulou C. Lefkothea, Fatouros G. Dimitrios. Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics. Expert Review of Precision Medicine and Drug Development, Volume 4, Issue 3, 2019, Apr. DOI: 10.1080/23808993.2019.1605828
42. Achilleas Kyriazopoulos, Aikaterini-Lamprini Alexiou, Androulla N. Miliotou, Lefkothea Papadopoulou, Antonios Hatzidimitriou, Dionysia Papagiannopoulou. Effect of the triphenylphosphonium cation on the biological properties of new rhenium and technetium-99m fac-[M(CO)3(NSN)]+-type complexes: Synthesis, structural characterization, in vitro and in vivo studies. Inorganica Chimica Acta, Volume 511, 1 October 2020, 119807 DOI: 10.1016/j.ica.2020.119807
43. Isaia Symeonidou, Athanasios Gelasakis, Androulla Miliotou, Athanasios Angelou, Konstantinos Arsenopoulos, Sofia Loukeri, Elias Papadopoulos. Rapid on site diagnosis of canine giardiosis: time vs. Reliability. Parasites & Vectors 13 (1), 1-10, December 2020. DOI: 10.1186/s13071-020-04422-6
44. Georgios C. Kaiafas, Dionysia Papagiannopoulou, Αndroulla N. Miliotou, Anastasia S. Tsingotjidou, Parthenopi C. Chalkidou, Aikaterini C. Tsika, George A. Spyroulias, Asterios S. Tsiftsoglou, Lefkothea C. Papadopoulou. In vivo biodistribution study of TAT-L-Sco2 fusion protein, developed as protein therapeutic for mitochondrial disorders attributed to SCO2 mutations. Molecular Genetics and Metabolism Reports 25, 100683, December 2020 DOI: 10.1016/j.ymgmr.2020.100683
45. Androulla N. Miliotou, Dionysia Papagiannopoulou, Efthymia Vlachaki, Martina Samiotaki, Dimitra Laspa, Stamatia Theodoridou, Asterios S. Tsiftsoglou and Lefkothea C. Papadopoulou*
    PTD-mediated delivery of α-globin chain into Κ-562 erythroleukemia cells and α-thalassemic (HBH) patients’ RBCs ex vivo in the frame of Protein Replacement Therapy. Journal of Biological Research-Thessaloniki 28 (1), 1-13, 2021 DOI: 10.1186/s40709-021-00148-3
46. Miliotou N. Androulla, Pappas S. Ioannis, Spyroulias S. George, Vlachaki Efthimia, Tsiftsoglou S. Asterios, Vizirianakis S. Ioannis and Papadopoulou C. Lefkothea.
    Development of a novel PTD-mediated IVT-mRNA Delivery Platform for potential Clinical Application as a Protein Therapy approach for Metabolic/Genetic disorders. Molecular Therapy-Nucleic Acids, 26, 694-710, 2021 DOI: 10.1016/j.omtn.2021.09.008
47. Ioanna Sigala, Anastasia Koukiali, Androulla Miliotou, Phaedra Lougiaki, Thomas Giannakouros, Eleni Nikolakaki. An ATM/CHK2 signaling pathway induces nuclear translocation of SRPK2 in cisplatin-treated HeLa cells. Processes, 9 (12), 2223, 2021 DOI: 10.3390/pr9122223
48. Georgiou-Siafis K. Sofia, Miliotou N. Androulla, Nenti Charikleia, Pappas S. Ioannis, Papadopoulou C. Lefkothea. An Innovative PTD-IVT-mRNA Delivery Platform for CAR Immunotherapy of ErbB(+) Solid Tumor Neoplastic Cells. Biomedicines, 10 (11), 2885, 2022 DOI: 10.3390/biomedicines10112885
49. Panoraia I Siafaka, Ece Ozcan Bulbul, Androulla N Miliotou, Ioannis D Karantas, Mehmet Evren Okur, Neslihan Üstündağ Okur. Delivering active molecules to the eye; the concept of electrospinning as potent tool for drug delivery systems. Journal of Drug Delivery Science and Technology, 84 (104565), 2023 DOI: 10.1016/j.jddst.2023.104565
50. Androulla N Miliotou, Parthena F Foltopoulou, Alexandra Ingendoh-Tsakmakidis, Asterios S Tsiftsoglou, Ioannis S Vizirianakis, Ioannis S Pappas, Lefkothea C Papadopoulou
    Protein Transduction Domain-Mediated Delivery of Recombinant Proteins and In Vitro Transcribed mRNAs for Protein Replacement Therapy of Human Severe Genetic Mitochondrial Disorders: The Case of Sco2 Deficiency. Pharmaceutics, 15(1), 286, 2023 DOI: 10.3390/pharmaceutics15010286
51. Parthena F Foltopoulou. Androulla N Miliotou, Alexandra Ingendoh-Tsakmakidis, Asterios S Tsiftsoglou, Ioannis S Vizirianakis, Ioannis S Pappas, Lefkothea C Papadopoulou
    Mitochondrial Disorders. Encyclopedia Scholarly Community Encyclopedia – Neurodegeneration DOI: https://encyclopedia.pub/entry/40470
52. Panoraia I Siafaka, Androulla N Miliotou, Ioannis D Karantas. An updated review for hyperuricemia and gout management; special focus on the available drug delivery systems and clinical trials. Current Medicinal Chemistry. 2023. DOI: 10.2174/0929867331666230809143758
53. Miliotou N. Androulla, Georgiou-Siafis K. Sofia, Nenti Charikleia, Pappas S. Ioannis, Papadopoulou C. Lefkothea. Recruiting In Vitro Transcribed mRNA against Cancer Immunotherapy: A Contemporary Appraisal of the Current Landscape. Issues Mol. Biol., 45 (11), 9181-9214, 2023 DOI: 10.3390/cimb45110576
54. Georgios Tzovas, Nafsika Papadimitriou, Eirini Angelakarou, Georgia Bompola, Androulla N. Miliotou, Maria G. Kakafika, Lefkothea C. Papadopoulou, Ιoannis Iakovou, Catherine Gabriel, Dimosthenis Sarigiannis, Dionysia Papagiannopoulou. Synthesis and biological evaluation of 99mTc-tricarbonyl complexes of C-3 carboxy derivatives of fluoroquinolones in infection and tumor animal models. Inorganica Chimica Acta, Volume 562,121894, 2024 DOI: 10.1016/j.ica.2023.121894.
55. Panoraia I. Siafaka, Ece Özcan Bülbül, Androulla N. Miliotou, Ioannis D. Karantas, Mehmet Evren Okur, Neslihan Üstündağ Okur Nano-based carriers for pulmonary drug delivery: A review on the available drug delivery applications and toxicity issues. Journal of Drug Delivery Science and Technology, 105381, 2024 DOI: 10.1016/j.jddst.2024.105381.
56. Tsiftsoglou Kakafika, Lyta, Gavriilidis, Tsiftsoglou, Miliotou, Pappas, Vizirianakis, Papadopoulou Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‐562 and colorectal HCT‐116 cancer cells. International Journal of Oncology, 64, 42, DOI: 10.3892/ijo.2024.5630
57. N Topouzidou, C Petrou, AN Miliotou, Y Sarigiannis Genetic Insights into E-Cadherin Modulation: Exploring the Benefits of Synthetic Acetyl Hexapeptide-1 in Wound Healing and Anti-Aging for Dermo-Cosmetics. Proceedings, 103(1), 48, 2024.DOI: 10.3390/proceedings2024103048
58. Miliotou N. Androulla and Papadopoulou C. Lefkothea.In Vitro-Transcribed (IVT)-mRNA CAR Therapy Development. In: Swiech K., Malmegrim K., Picanço-Castro V. (eds)Chimeric Antigen Receptor T Cells. Methods in Molecular Biology, vol 2086. Humana, New York, NY, 2019, DOI: 10.1007/978-1-0716-0146-4_7
59. Miliotou N. Androulla, Pappas S. Ioannis, Vizirianakis S. Ioannis and Papadopoulou C. Lefkothea. In Vitro-Transcribed mRNAs as a new generation of therapeutics in the dawn of 21st century: Exploitation of peptides as carriers for their intracellular delivery. In: Stefan Jurga and Jan Barciszewski (eds). Messenger RNA Therapeutics, RNA TECHNOLOGIES, Springer Series, vol13, 2022. DOI: 10.1007/978- 3-031-08415-7_10
60. Miliotou N. Androulla, Georgiou-Siafis Sofia, Vlachaki Efthymia, Pappas S. Ioannis, Vizirianakis S. Ioannis, Tsiftsoglou S. Asterios and Papadopoulou C. Lefkothea.Conventional and innovative molecular approaches developed for treating hemoglobinopathies. In: Comprehensive Hematology and Stem Cell Research, Major Reference Workbook chapter by Elsevier, 2024. DOI: 10.1016/B978-0-443-15717-2.00025-1
61. Antoniou V, Mourelatou EA, Galatou E, Avgoustakis K, Hatziantoniou S. Gene Therapy with Chitosan Nanoparticles: Modern Formulation Strategies for Enhancing Cancer Cell Transfection. Pharmaceutics. 2024 Jun 27;16(7):868. doi: 10.3390/pharmaceutics16070868. PMID: 39065565; PMCID: PMC11280172.
62. Elena A Mourelatou, Elias Iosif, Eleftheria Galatou, Yiannis Sarigiannis, Manos C Vlasiou, Lefteris Zacharia, Christos C Petrou (2024). “Application of artificial intelligence in pharmaceutical formulation development” in. Novel Formulations and Future Trends (pp.415-451) DOI:10.1016/B978-0-323-91816-9.00009-6
63. Ravingerova T, Adameova A, Lonek L, Farkasova V, Ferko M, Andelova N, Kura B, Slezak J, Galatou E, Lazou A, Zohdi V, Dhalla NS. Is Intrinsic Cardioprotection a Laboratory Phenomenon or a Clinically Relevant Tool to Salvage the Failing Heart? Int J Mol Sci. 2023 Nov 18;24(22):16497. doi: 10.3390/ijms242216497. PMID: 38003687; PMCID: PMC10671596.
64. Palioura D, Mellidis K, Ioannidou-Kabouri K, Galatou E, Mouchtouri ET, Stamatiou R, Mavrommatis-Parasidis P, Panteris E, Varela A, Davos C, Drosatos K, Mavroidis M, Lazou A. PPARδ activation improves cardiac mitochondrial homeostasis in desmin deficient mice but does not alleviate systolic dysfunction. J Mol Cell Cardiol. 2023 Aug 19;183:27-41. doi: 10.1016/j.yjmcc.2023.08.005. Epub ahead of print. PMID: 37603971.
65. Saiti, A.; Giannopoulos-Dimitriou, A.; Kazakos, I.; Galatou, E.; Vizirianakis, I. Systems Pharmacology and Network Analysis to Advance Pharmacogenomics and Precision Medicine Decisions in Type-2 Diabetes Therapy. Future Pharmacol. 2023, 3(1), 329-363; https://doi.org/10.3390/futurepharmacol3010021. https://www.mdpi.com/2673-9879/3/1/21
66. Papaneophytou C, Nicolaou A, Pieri M, Nicolaidou V, Galatou E, Sarigiannis Y, Pantelidou M, Panayi P, Thoma T, Stavraki A, Argyrou X, Kalogiannis T, Yiannoukas K, Petrou CC, Felekkis K. Seroprevalence of immunoglobulin G antibodies against SARS-CoV-2 in Cyprus. PLoS One. 2022 Jun 13;17(6):e0269885. doi: 10.1371/journal.pone.0269885. PMID: 35696396; PMCID: PMC9191710.
67. Mourelatou E, Galatou E, Zacharia L, Sarigiannis I, Petrou C. Chapter 25 – Clinical trials of nanovesicles for drug delivery uses in “Applications of Nanovesicular Drug Delivery” Eds.; Academic Press, 2022; pp. 467–486 ISBN 978-0-323-91865-7.
68. Galatou E, Mourelatou E, Hatziantoniou S, Vizirianakis IS. Nonalcoholic Steatohepatitis (NASH) and Atherosclerosis: Explaining Their Pathophysiology, Association and the Role of Incretin-Based Drugs. Antioxidants (Basel). 2022 May 27;11(6):1060. doi: 10.3390/antiox11061060. PMID: 35739957
69. Chatzopoulou, F., Kyritsis, K. A., Papagiannopoulos, C. I., Galatou, E., Mittas, N., Theodoroula, N. F., Papazoglou, A. S., Karagiannidis, E., Chatzidimitriou, M., Papa, A., Sianos, G., Angelis, L., Chatzidimitriou, D., & Vizirianakis, I. S. (2022). Dissecting miRNA-Gene Networks to Map Clinical Utility Roads of Pharmacogenomics-Guided Therapeutic Decisions in Cardiovascular Precision Medicine. Cells, 11(4), 607. https://doi.org/10.3390/cells11040607
70. Theodoroula, N. F., Karavasili, C., Vlasiou, M. C., Primikyri, A., Nicolaou, C., Chatzikonstantinou, A. V., Chatzitaki, A. T., Petrou, C., Bouropoulos, N., Zacharis, C. K., Galatou, E., Sarigiannis, Y., Fatouros, D. G., & Vizirianakis, I. S. (2022). NGIWY-Amide: A Bioinspired Ultrashort Self-Assembled Peptide Gelator for Local Drug Delivery Applications. Pharmaceutics, 14(1), 133. https://doi.org/10.3390/pharmaceutics14010133
71. Lecour S, Andreadou I, Bøtker HE, Davidson SM, Heusch G, Ruiz-Meana M, Schulz R, Zuurbier CJ, Ferdinandy P, Hausenloy DJ; the European Union-CARDIOPROTECTION COST ACTION CA16225. IMproving Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol. 2021 Sep 13;116(1):52.
72. Papatheodorou I, Galatou E, Panagiotidis G-D, Ravingerová T, Lazou A. Cardioprotective Effects of PPARβ/δ Activation against Ischemia/Reperfusion Injury in Rat Heart Are Associated with ALDH2 Upregulation, Amelioration of Oxidative Stress and Preservation of Mitochondrial Energy Production. International Journal of Molecular Sciences. 2021; 22(12):6399.
73. Eleftheria Galatou, Antigone Lazou. Long Noncoding and Circular RNAs as therapeutic targets in myocardial and cerebral ischemia/reperfusion injury. Conditioning Medicine 2020, 3(1): 47-57
74. Papaneophytou C., Galatou E., Felekkis K. (2020) Good laboratory and experimental practices for microRNA analysis in cardiovascular research in “Epigenetics in Cardiovascular Disease” Epigenetics in Cardiovascular Disease, e-book Chapter 18 (24) 395-414.
75. Ioannou Andreadou, Pavle Adamovski, Monika Bartekova, Christophe Beauloye, Luc Bertrand, David Biedermann, Vilmante Borutaite, Hans Erik Bøtker, Stefan Chlopicki, Maija Dambrova, Sean Davidson,Yvan Devaux, Fabio Di Lisa, Dragan Djuric, David Erlinge, Inês Falcao-Pires, Eleftheria Galatou et al. Realizing the therapeutic potential of novel cardioprotective therapies: The EU-CARDIOPROTECTION COST Action – CA16225. Conditioning Medicine, 2018, 1(3):116-123
76. Feidantsis Κ, Mellidis K, Galatou Ε, Sinakos Z, Lazou A. Treatment with crocin improves cardiac dysfunction by normalizing autophagy and inhibiting apoptosis in STZ-induced diabetic cardiomyopathy. Nutr Metab Cardiovasc Dis 2018 Sep;28(9):952-961.
77. Barlaka E, Galatou E, Mellidis K, Ravingerova T, Lazou A. Role of pleiotropic properties of peroxisome proliferator-activated receptors in the heart: focus on the non-metabolic effects in cardiac protection. Cardiovasc Ther. 2016 Feb;34(1):37-48.
78. Galatou E, Kelly T, Lazou A. The PPARβ/δ agonist GW0742 modulates signaling pathways associated with cardiac myocyte growth via a non-genomic redox mechanism. Mol Cell Biochem. 2014 Oct;395(1-2):145-54.
79. Mellidis K, Ordodi V, Galatou E, Săndesc D, Bubenek S, Duicu O, Muntean D, Lazou A. Activation of prosurvival signaling pathways during the memory phase of volatile anesthetic preconditioning in human myocardium: a pilot study. Mol Cell Biochem. 2014 Mar;388(1-2):195-201.
80. Ravingerova; S. Carnicka; V. Ledvenyiova; E. Barlaka; E. Galatou; P. Mandikova; A. Chytilova; M. Nemcekova; F. Kolar; A. Lazou. Delayed preconditioning-like protection against ischemia/reperfusion injury in the rat heart is associated with PPAR-alpha-mediated changes in metabolic genes and non-metabolic effects. Cardiovascular Research Supplements (2014) 103, S57–S94
81. Barlaka E, Ledvényiová V, Galatou E, Ferko M, Čarnická S, Ravingerová T, Lazou A. Delayed cardioprotective effects of WY-14643 are associated with inhibition of MMP-2 and modulation of Bcl-2 family proteins through PPAR-α activation in rat hearts subjected to global ischaemia-reperfusion. Can J Physiol Pharmacol. 2013 Aug;91(8):608-16.
82. Ravingerová T, Carnická S, Ledvényiová V, Barlaka E, Galatou E, et al (2013). Upregulation of genes involved in cardiac metabolism enhances myocardial resistance to ischemia/reperfusion in the rat heart. Physiol Res. 2013 Dec 12;62 Suppl 1:S151-63.
83. Ravingerová T, Carnická S, Nemčeková M, Ledvényiová V, Adameová A, Kelly T, Barlaka E, Galatou E, Khandelwal VK, Lazou A. PPAR-alpha activation as a preconditioning-like intervention in rats in vivo confers myocardial protection against acute ischaemia-reperfusion injury: involvement of PI3K-Akt. Can J Physiol Pharmacol. 2012 Aug;90(8):1135-44.
84. Ravingerova T, Adameova A, Carnicka S, Nemcekova M, Kelly T, Matejikova J, Galatou E, Barlaka E, Lazou A. The role of PPAR in myocardial response to ischemia in normal and diseased heart. Gen Physiol Biophys. 2011 Dec;30(4):329-41.
85. Markou T, Makridou Z, Galatou E, Lazou A. Multiple signaling pathways underlie the protective effect of levosimendan in cardiac myocytes. Eur J Pharmacol. 2011 Sep 30;667(1-3):298-305.